p38 MAP kinase inhibitors
US8293771B2 · kind B2 · utility
44Cited by
4References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2009 |
| Grant date | Oct 23, 2012 |
| Priority date | — |
| Expiry date | Oct 2, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.